Angiotensin (1-7) vs Endoluten

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas receptor to promote vasodilation, anti-fibrotic, anti-inflammatory, and cardioprotective effects that oppose the vasoconstrictive actions of angiotensin II. Ang-(1-7) acts through the ACE2/Mas receptor axis to reduce oxidative stress, attenuate NF-kB-mediated inflammation, and suppress TGF-beta fibrosis signaling; the ACE2/Ang-(1-7)/Mas axis has emerged as a key regulatory pathway in cardiovascular and metabolic disease, and gained renewed research attention given ACE2's role as the SARS-CoV-2 entry receptor. A Phase 1-2 randomized clinical trial of Ang-(1-7) infusion in COVID-19 ICU patients reported preliminary safety, tolerability, and dose-response data, providing the primary indexed human pharmacokinetic evidence; broader cardiovascular protective applications are supported by preclinical data but have not been established by completed Phase 3 trials. Ang-(1-7) has no FDA approval and no approved therapeutic indication in any jurisdiction; it is an endogenous peptide under active clinical investigation as a candidate for cardiovascular, metabolic, and inflammatory conditions, with emerging human safety data but an incomplete evidence base for any specific approved clinical use.

Pineal-targeted peptide complex that modulates melatonin synthesis pathways and circadian gene expression. May help restore age-related decline in pineal activity and improve circadian rhythm regulation.

Endoluten is a Khavinson-class peptide bioregulator derived from pineal gland tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore physiological circadian regulation and melatonin synthesis by modulating gene expression in aging pineal epithelial cells through interaction with chromatin regulatory elements. As a pineal tissue-derived bioregulator, Endoluten operates within the mechanistic framework established for the Khavinson class: short peptides (2–4 amino acids) are proposed to bind specific DNA regulatory sequences in tissue-target cells, activating gene expression programs that decline with age and restoring physiological function through epigenetic mechanisms rather than receptor agonism. Published research on Khavinson-class peptide bioregulators as a class has characterized this peptide-DNA interaction mechanism and documented restorative effects on tissue-specific physiological parameters in aging animal models and human observational studies, providing class-level biological plausibility for pineal peptide bioregulators as age-related circadian and neuroendocrine regulators. Endoluten has no FDA approval and no approved indication in any Western jurisdiction; no indexed published studies using the Endoluten name specifically characterize its clinical outcomes in controlled trials, and its use is confined to the Russian integrative and anti-aging medicine context where Khavinson bioregulators are commercially available.